238 related articles for article (PubMed ID: 30871932)
1. A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora.
Belén LH; Lissabet JB; de Oliveira Rangel-Yagui C; Effer B; Monteiro G; Pessoa A; Farías Avendaño JG
Biologicals; 2019 May; 59():47-55. PubMed ID: 30871932
[TBL] [Abstract][Full Text] [Related]
2. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Pokrovsky VS; Kazanov MD; Dyakov IN; Pokrovskaya MV; Aleksandrova SS
BMC Cancer; 2016 Feb; 16():89. PubMed ID: 26867931
[TBL] [Abstract][Full Text] [Related]
3. Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.
Ramya LN; Pulicherla KK
Pathol Oncol Res; 2015 Sep; 21(4):909-20. PubMed ID: 25740072
[TBL] [Abstract][Full Text] [Related]
4. Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.
Huerta-Saquero A; Evangelista-Martínez Z; Moreno-Enriquez A; Perez-Rueda E
Bioengineered; 2013; 4(1):30-6. PubMed ID: 22895060
[TBL] [Abstract][Full Text] [Related]
5. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Billett AL; Carls A; Gelber RD; Sallan SE
Cancer; 1992 Jul; 70(1):201-6. PubMed ID: 1606543
[TBL] [Abstract][Full Text] [Related]
6. [Cross-immunogenicity of various bacterial L-asparaginases].
D'iakov IN; Pokrovskiĭ VS; Sannikova EP; Bulushova NV; Pokrovskaia MV; Aleksandrova SS
Zh Mikrobiol Epidemiol Immunobiol; 2014; (6):100-4. PubMed ID: 25816523
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional insights into Erwinia carotovora L-asparaginase.
Papageorgiou AC; Posypanova GA; Andersson CS; Sokolov NN; Krasotkina J
FEBS J; 2008 Sep; 275(17):4306-16. PubMed ID: 18647344
[TBL] [Abstract][Full Text] [Related]
9. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
10. One-step purification and kinetic properties of the recombinant L-asparaginase from Erwinia carotovora.
Krasotkina J; Borisova AA; Gervaziev YV; Sokolov NN
Biotechnol Appl Biochem; 2004 Apr; 39(Pt 2):215-21. PubMed ID: 15032742
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL).
Avramis VI; Avramis EV; Hunter W; Long MC
Anticancer Res; 2009 Jan; 29(1):299-302. PubMed ID: 19331165
[TBL] [Abstract][Full Text] [Related]
12. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
13. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment.
Werner A; Röhm KH; Müller HJ
Biol Chem; 2005 Jun; 386(6):535-40. PubMed ID: 16006240
[TBL] [Abstract][Full Text] [Related]
14. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R
Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
[TBL] [Abstract][Full Text] [Related]
15. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Figueiredo L; Cole PD; Drachtman RA
Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
[TBL] [Abstract][Full Text] [Related]
16. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
17. Cloning, expression and characterisation of Erwinia carotovora L-asparaginase.
Kotzia GA; Labrou NE
J Biotechnol; 2005 Oct; 119(4):309-23. PubMed ID: 15951039
[TBL] [Abstract][Full Text] [Related]
18. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
19. [Purification and properties of recombinant Erwinia carotovora L-asparaginase expressed in E.coli cells].
Borisova AA; El'darov MA; Zhgun AA; Aleksandrova SS; Omel'ianiuk NM; Sokov BN; Berezov TT; Sokolov NN
Biomed Khim; 2003; 49(5):502-7. PubMed ID: 16119104
[TBL] [Abstract][Full Text] [Related]
20. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
Wacker P; Land VJ; Camitta BM; Kurtzberg J; Pullen J; Harris MB; Shuster JJ;
J Pediatr Hematol Oncol; 2007 Sep; 29(9):627-32. PubMed ID: 17805038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
